Multispecific ISVD Polypeptides for Dual IL-13 and OX40L Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as asthma and atopic dermatitis, are inadequate for a subpopulation of patients, and dual targeting of IL-13 and OX40L is lacking in active clinical development programs, while co-administration of separate biologicals poses practical and commercial challenges.
Innovation Solution
Development of bi- or multi-specific polypeptides, termed immunoglobulin single variable domain (ISVD) constructs, that simultaneously target IL-13 and OX40L, offering improved efficacy and convenience by reducing the need for multiple injections and addressing production and stability issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used for treatment, then type 2 pathway blocking is achieved, but a subpopulation of patients does not respond optimally
Solution Approach 1:
The patent creates bispecific antibodies that can simultaneously bind to two different targets (IL-13 and OX40L), allowing a single therapeutic agent to address multiple immune pathways involved in inflammatory diseases. This multi-functionality enables broader patient response coverage compared to conventional monospecific antibodies.
Solution Approach 2:
The invention employs composite antibody structures combining different antigen-binding specificities within a single molecular entity. The bispecific antibodies integrate both anti-IL-13 and anti-OX40L binding capabilities, creating a composite therapeutic material that addresses limitations of single-specificity antibodies.
2Reliability
If separate biologicals are co-administered to target multiple factors, then comprehensive disease coverage is achieved, but practical and commercial challenges arise
Solution Approach 1:
The patent merges the functionality of multiple separate biological agents into a single bispecific antibody molecule. By combining anti-IL-13 and anti-OX40L specificities in one therapeutic agent, the invention eliminates the need for co-administration of separate drugs, thereby improving administration convenience while maintaining comprehensive disease coverage.
Solution Approach 2:
The bispecific antibody serves multiple therapeutic functions simultaneously, replacing the need for multiple separate medications. This multi-functional approach simplifies the treatment regimen from multiple injections to a single administration while achieving comparable or superior disease coverage.
3Reliability
If dual targeting of IL-13 and OX40L is implemented, then improved efficacy is achieved, but production and stability issues must be addressed
Solution Approach 1:
The patent employs various engineering strategies to optimize the bispecific antibody structure for improved production feasibility and stability. This includes modifying amino acid sequences, adjusting structural configurations, and optimizing expression conditions to enhance manufacturability while preserving the dual-targeting efficacy.
Data Source
AI summary
The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.